U.S. FDA grants accelerated approval to Bayer's targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer
September 09, 2026
September 09, 2026
LEVERKUSEN, Germany, Sept. 9 [Category: BizPharmaceuticals] -- Bayer Group, a pharmaceutical and life sciences company, posted the following news release:
* * *
U.S. FDA grants accelerated approval to Bayer's targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer
*
Berlin, September 9, 2026 - Following Priority Review and Breakthrough Therapy Designation, the U.S. Food and Drug . . .
* * *
U.S. FDA grants accelerated approval to Bayer's targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer
*
Berlin, September 9, 2026 - Following Priority Review and Breakthrough Therapy Designation, the U.S. Food and Drug . . .